ReviewWorld journal of microbiology & biotechnology2025
Harnessing microbial nanobiotics: Lactobacillus extracellular vesicles as next-generation therapeutics across physiological systems.
Review in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Probiotic extracellular vesicles reprogram macrophage immunometabolism: From gut crosstalk to host health.Gut microbes · 2026Review
- Extracellular vesicle-like nanoparticles from Lactobacillus delbrueckii protect keratinocyte barrier function with involvement of TRPV4 signaling.World journal of microbiology & biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactobacillus-derived extracellular vesicles (LEVs) are emerging as pivotal mediators of interkingdom communication, carrying strain-specific bioactive cargo that influences diverse physiological systems, including the gut, nervous, respiratory, reproductive, and integumentary systems. These nanoscale structures demonstrate significant therapeutic potential, modulating host immunity, enhancing barrier integrity, combating pathogens, and contributing to tissue repair across numerous health contexts. However, realizing their full clinical and biotechnological promise faces substantial hurdles. Key challenges include variability in isolation and purification methods, inconsistencies in LEV yield and composition due to cultivation conditions and inherent strain differences, and the observation of context-dependent or even paradoxical effects in certain diseases. Furthermore, gaps persist in understanding their precise biogenesis, cargo sorting mechanisms, and long-term biodistribution. Future progress necessitates interdisciplinary efforts to standardize production and characterization, resolve mechanistic ambiguities, and develop robust bioengineering strategies for targeted delivery and enhanced functionality. Addressing these obstacles is crucial to harness LEVs effectively as versatile tools in precision medicine, microbiome engineering, and sustainable applications in health and industry.
Indexed as
Identifiers
40640466What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.